Goldman Sachs
TLOG

Goldman Sachs’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History

Goldman Sachs’s Portfolio TLOG Stock Details TLOG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-44,131
Closed -$7K – 7300
2016
Q3 		$7K Buy
44,131
+2,220
+5% +$513 ﹤0.01% 6910
2016
Q2 		$13K Sell
41,911
-12,255
-23% -$3.41K ﹤0.01% 6821
2016
Q1 		$10K Buy
54,166
+28,372
+110% +$7.88K ﹤0.01% 6907
2015
Q4 		$45K Buy
25,794
+13,973
+118% +$24.6K ﹤0.01% 6595
2015
Q3 		$22K Sell
11,821
-13,328
-53% -$31.7K ﹤0.01% 7016
2015
Q2 		$59K Sell
25,149
-5,961
-19% -$18.4K ﹤0.01% 6829
2015
Q1 		$136K Sell
31,110
-9,855
-24% -$49.5K ﹤0.01% 6279
2014
Q4 		$197K Sell
40,965
-6,698
-14% -$30K ﹤0.01% 6167
2014
Q3 		$198K Buy
47,663
+9,810
+26% +$45.7K ﹤0.01% 6173
2014
Q2 		$223K Sell
37,853
-14,213
-27% -$80.6K ﹤0.01% 6122
2014
Q1 		$332K Sell
52,066
-2,799
-5% -$25.2K ﹤0.01% 5652
2013
Q4 		$522K Buy
+54,865
New +$428K ﹤0.01% 5264

Other funds holding TLOG

California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
BWA
Burt Wealth Advisors North Bethesda, Maryland $407M AUM 11.98% 1-Year Est. Return

Goldman Sachs's TLOG Position: Q4 2016 in Review

Goldman Sachs sold out of TetraLogic Pharmaceuticals Corporation (TLOG) in Q4 2016, closing a stake of 44,131 shares — an estimated $7K sold.

Goldman Sachs first reported a position in TLOG in Q4 2013 and held it in 12 quarters. The position peaked at $522K in Q4 2013. 3 funds tracked by Wall St. Rank hold TLOG as of Q4 2016.

  • Goldman Sachs reported no remaining TetraLogic Pharmaceuticals Corporation position as of Q4 2016 after selling out during the quarter.
  • Goldman Sachs sold 44,131 TetraLogic Pharmaceuticals Corporation shares in Q4 2016, an estimated $7K.
  • Goldman Sachs first reported a position in TetraLogic Pharmaceuticals Corporation in Q4 2013 and held it in 12 quarters.
  • Goldman Sachs's TetraLogic Pharmaceuticals Corporation position peaked at $522K in Q4 2013.
  • 3 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q4 2016.

Based on Goldman Sachs's 13F filing for Q4 2016, filed 14 Feb 2017.